Shennon Biotechnologies Company Research Report

Company Overview

• Name: Shennon Biotechnologies Inc.

• Mission: To analyze, understand, and manipulate massive numbers of cells at the single-cell level to develop more effective treatments for human diseases.

• Founded: 2021

• Founders: Information not explicitly provided; the founding team set out to solve bottlenecks in immune cell profiling at Harvard University.

• Key People:

• Li Sun, PhD - CEO & Founder

• Kaveh Milaninia, PhD - CTO & Head of Platform

• Kaitao Li, PhD - Associate Director

• Ian Chen, PhD - Staff Platform Engineer

• Michael Malone, PhD - Senior Scientist

• Headquarters: 2325 3rd Street, Suite 327-328, San Francisco, CA 94107

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Developing a proprietary ultra-high throughput single-cell platform to profile millions of immune cells at the single-cell level, focusing on generating targeted immunotherapies.

Products

• Proprietary Single Cell Platform

• Description: An advanced platform that performs functional profiling of millions of immune cells simultaneously at the single-cell level. It's designed to identify rare and difficult-to-find targets that can considerably enhance the efficacy of immunotherapies.

• Key Features:

• Ultra-high throughput capability allowing the processing of millions of cells within an hour.

• Focuses on creating targeted and effective immunotherapies, particularly for solid tumors.

Recent Developments

• Seed Financing: Recently, Shennon Biotechnologies successfully raised $13 million in seed funding led by DCVC, with participation from Foundation Capital, AV8, and other angel investors. The financing round was oversubscribed.

• New Products/Features:

• The seed funding is aimed at further expanding the capabilities of Shennon Bio’s proprietary platform and enhancing discovery efforts for effective targets for solid tumors.

• Partnerships:

• The company has established collaborations with multiple clinical centers to study patient samples and scale discovery efforts.

• Continues to work with clinical and pharmaceutical partners to run clinical trials and develop targeted therapies.

Media Contact:

• Kimberly Ha, KKH Advisors - kimberly.ha@kkhadvisors.com

For more detailed and up-to-date information, visit their official website at [shennonbio.com](http://www.shennonbio.com).